Investors Eye Catching Stocks : (NYSE : PFE), (NYSE : GE)
Pfizer Inc. (NYSE: PFE) recently announced that its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for the potential treatment of patients with breast cancer.
View full press release